PSA levels are subject to transient variations, and there is a significant lag time between PSA response and treatment effect or relapse, requiring confirmatory, clinically detectable changes in tumour volume in order to alter treatment regimens6,7. The gene discussed is KLK3; the disease is neoplasm.